Other languages Kiora Pharmaceuticals, Inc.

Equities

KPRX

US49721T3095

Delayed Nasdaq Other stock markets 15:47:21 14/05/2024 BST			5-day change	1st Jan Change
0.5039 ^USD	-1.14%		+0.58%	-3.54%

05-10	Earnings Flash (KPRX) KIORA PHARMACEUTICALS Posts Q1 Revenue $16M	MT
03-25	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-25
Kiora Pharmaceuticals Grants License to Thea Open for Molecular Photoswitch Product - Shares Surge	02-01
Kiora Pharmaceuticals, Inc. Enters into an Exclusive License and Development Agreement with Théa Open Innovation SAS	01-31
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Kiora Pharmaceuticals, Inc. Announces Board Changes	21/09/23
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/08/23
Kiora Pharmaceuticals, Inc. Appoints Carmine Stengone as an Independent Director	01/08/23
Kiora Pharmaceuticals, Inc. Enters into an Intellectual Property License Agreement with Sentrx Animal Care, Inc	15/06/23
Sector Update: Health Care Stocks Rising Late Friday	02/06/23
Sector Update: Health Care Stocks Rising Friday Afternoon	02/06/23
Top Midday Decliners	02/06/23
Kiora Pharmaceuticals Prices $5.5 Million Public Offering; Shares Drop	02/06/23
Top Premarket Decliners	02/06/23
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/05/23
Kiora Pharmaceuticals Presents Preliminary Results from an Ongoing Clinical Trial Showing its Investigational Drug, KIO-301	27/04/23
Kiora Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	22/03/23
Kiora Pharmaceuticals, Inc. and The Royal Adelaide Hospital Announce Dosing Has Commenced in the Phase 1 First-In-Human Trial for KIO-301	14/02/23
Kiora Pharmaceuticals, Inc. Receives Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases	07/02/23
Kiora Pharmaceuticals Completes Enrollment in Eye Therapy KIO-201 Study	03/01/23
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	09/11/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Kiora Pharmaceuticals, Inc.

Equities

KPRX

US49721T3095

Other languages

Filters